Document:

<PAGE>
                                                                   EXHIBIT 10.37

                          PATRIOT CAPITAL FUNDING, INC.
                              274 RIVERSIDE AVENUE
                               WESTPORT, CT 06880

                                 March 28, 2006

Dover Saddlery, Inc.
525 Great Road
Littleton, MA  01460
Attn: Stephen L. Day

      Re:   Amendment No. 1 to the Amended and Restated Senior Subordinated Note
            and Warrant Purchase Agreement ("Amendment No. 1")

Stephen:

Reference is made to the Amended and Restated Senior Subordinated Note and
Warrant Purchase Agreement, dated as of September 16, 2005 (the "Note Purchase
Agreement"), among Dover Saddlery, Inc., a Delaware corporation (the "Parent"),
Dover Saddlery, Inc., a Massachusetts corporation and wholly-owned subsidiary of
Parent ("Operating Company #1"), Smith Brothers, Inc., a Texas corporation and
wholly-owned subsidiary of Parent ("Operating Company #2" and, together with
Parent and Operating Company #1, the "Loan Parties"), Patriot Capital Funding
LLC I ("Purchaser") and the undersigned ("Servicer"). Capitalized terms used
herein and not otherwise defined shall have the meanings ascribed to such terms
in the Note Purchase Agreement.

The parties to the Note Purchase Agreement desire to make certain amendments
thereto and, pursuant to Sections 9.10(b) and 10.2 of the Note Purchase
Agreement, such amendments must be in a written instrument signed by the Loan
Parties, Servicer and the Required Purchasers. Purchaser, as sole holder of the
Notes, constitutes the Required Purchasers for purposes of executing this
Amendment No. 1.

Therefore, the parties hereto, intending to be legally bound, hereby agree as
follows:

1.  AMENDMENT TO NOTE PURCHASE AGREEMENT.  All of the terms and provisions of
the Note Purchase Agreement shall remain in full force and effect except as
follows:

      (i) SECTION 1.1. The definition of "Total Debt Service" in Section 1.1 of
the Note Purchase Agreement is hereby amended and restated in its entirety to
read as follows:

            "Total Debt Service" means, for any period, the sum of, for all Loan
Parties taken as a whole, (i) Interest Charges on all Indebtedness for such
period, plus (ii) the aggregate amount of all regularly scheduled principal
payments made or coming due during such period in respect of the Senior
Financing or any other Indebtedness for borrowed money or capital lease (to the
extent the Servicer from time to time permits such Indebtedness to be incurred);
provided,

<PAGE>

however, that solely for purposes of this definition, Interest Charges shall
exclude (x) prepayment fees or premiums on the Notes and (y) amortization of
fees arising under the Notes, the Warrants, the Senior Financing and the private
financing.

      (II) SECTION 7.3(d). Section 7.3(d) of the Note Purchase Agreement is
hereby amended and restated in its entirety to read as follows:

            (d) MINIMUM EBITDA AMOUNT. Minimum EBITDA for the then preceding
four quarters of not less than:

<Table>
<Caption>
                            Period                       Minimum Amount
                            ------                       --------------
<S>                                                      <C>
      For each of the four fiscal quarters ending on     $3,400,000
      March 31, 2006
      For each of the four fiscal quarters ending on     $3,000,000
      June 30, 2006 and September 30, 2006
      For each of the four fiscal quarters ending on     $3,800,000
      December 31, 2006
      For any fiscal quarter ending on or after March    $5,000,000
      31, 2007
</Table>

2. AMENDMENT FEE; EXPENSES. In consideration of the Servicer's and Purchaser's
execution and delivery of this Amendment No. 1 and the amendments contained
herein, the Loan Parties shall pay to Servicer on the date hereof a fully earned
and non-refundable amendment fee (the "Amendment Fee") in the amount of Seven
Thousand Five Hundred Dollars ($7,500.00). The Loan Parties shall also pay all
reasonable expenses incurred by the Servicer and Purchaser in the drafting,
review, negotiation and closing of the documents and transactions contemplated
hereby, including the reasonable fees and disbursements of Servicer's special
counsel.

3. REAFFIRMATION. Except for the amendments specifically provided herein, the
Note Purchase Agreement shall remain unmodified and in full force and effect and
is hereby reaffirmed. In addition, this Amendment No. 1 shall not be deemed a
waiver of any term or condition of the Note Purchase Agreement or any other
Transaction Document, and shall not be deemed to prejudice any right or rights
which any party may now have or may have in the future under or in connection
with the Note Purchase Agreement or any other Transaction Document, as the same
may be amended from time to time.

4.  REPRESENTATIONS.  To induce Servicer and Purchaser to enter into this
Amendment No. 1, the Loan Parties, jointly and severally, represent and
warrant to Servicer and Purchaser that: (i) each Loan Party has the full
power and authority to enter into and perform its obligations under this
Amendment No. 1; and (ii) the consummation of the events and transactions
contemplated by this Amendment No. 1 do not conflict with, or result in any
violation of or default under any agreements with any third parties.

5.  CONDITIONS TO EFFECTIVENESS.  This Amendment No. 1 shall not be effective
until such date as the Servicer shall have received the following, all in
form, scope and content acceptable to

                                       2
<PAGE>

Servicer and Purchaser in their sole discretion: (i) this Amendment No. 1, duly
executed by the parties hereto; (ii) the $7,500.00 Amendment Fee; and (iii) a
waiver and amendment of the Senior Credit Agreement duly executed by the Senior
Lender.

6.  MISCELLANEOUS.  This Amendment No. 1 shall be governed by and construed
in accordance with the laws of the State of New York, without giving effect
to principles of conflicts of law.  This Amendment No. 1 may be executed in
two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.  Delivery of
an executed signature page to this Amendment No. 1 by facsimile transmission
shall be as effective as delivery of a manually signed counterpart hereof or
thereof.

                            [Signature page follows]

                                       3
<PAGE>

                                       Very truly yours,

                                       PATRIOT CAPITAL FUNDING, INC.

                                       By: /s/Timothy W. Hassler
                                           Timothy W. Hassler
                                           Chief Operating Officer

                                       By: /s/ Clifford L. Wells
                                           Clifford L. Wells
                                           Chief Investment Officer

SIGNATURE PAGE TO AMENDMENT NO. 1 TO NOTE PURCHASE AGREEMENT

<PAGE>

ACKNOWLEDGED and AGREED
this 28th day of March, 2006

PURCHASER

PATRIOT CAPITAL FUNDING LLC I

By: /s/Timothy W. Hassler
    Timothy W. Hassler
    Chief Operating Officer

By: /s/ Clifford L. Wells
    Clifford L. Wells
    Chief Investment Officer

LOAN PARTIES

PARENT:

DOVER SADDLERY, INC.

By: /s/ Stephen L. Day
    Stephen L. Day
    President

OPERATING COMPANY #1

DOVER SADDLERY, INC.

By: /s/ Stephen L. Day
    Stephen L. Day
    President

OPERATING COMPANY #2

SMITH BROTHERS, INC.

By: /s/ Stephen L. Day
    Stephen L. Day
    President

SIGNATURE PAGE TO AMENDMENT NO. 1 TO NOTE PURCHASE AGREEMENT<PAGE>

                                                                   EXHIBIT 10.20

                                LICENSE AGREEMENT
                               (Agreement ID 1101)

THIS LICENSE AGREEMENT is made and entered into as of February 28, 2005 (the
"Effective Date"), by and between the PURDUE RESEARCH FOUNDATION, a statutory
body corporate formed and existing under the Indiana Foundation or Holding
Companies Act of 1921 (hereinafter referred to as "PRF"), and ANDARA LIFE
SCIENCE, INC. (hereinafter referred to as "LICENSEE") collectively referred to
hereinafter as the "Parties."

                                   WITNESSETH

WHEREAS, PRF is the assignee of the right, title, and interest in the materials
described in Exhibit A (Licensed Patents and Licensed IP, as herein defined);
and

WHEREAS, PRF wishes to have the inventions further developed and marketed at the
earliest possible time in order that products resulting therefrom may be
available for public use and benefit; and

WHEREAS, LICENSEE wishes to obtain certain rights to pursue the development and
commercialization of the inventions; and

WHEREAS, PRF wishes to grant LICENSEE such rights in accordance with the terms
and conditions of this Agreement.

NOW, THEREFORE, for and in consideration of the mutual covenants and the
premises herein contained, the Parties, intending to be legally bound, hereby
agree as follows.

                             Article 1.  DEFINITIONS

The following terms as used herein shall have the following meaning:

       1.1    "Affiliate" shall mean any corporation, limited liability company,
partnership, or other business entity directly or indirectly controlled by, or
under common control with, LICENSEE.

       1.2    "Agreement" or "License Agreement" shall mean this Agreement,
including all Exhibits attached to this Agreement.

       1.3    "Attributable Quarterly Gross Receipts * * *" shall mean Quarterly
Gross Receipts directly attributable to Licensed Product(s) that are based on a
Technology where the Licensed Product(s) are intended for * * *.

       1.4    "Attributable Quarterly Cross Receipts * * *" shall mean Quarterly
Gross Receipts directly attributable to Licensed Product(s) that are based on a
Technology where the Licensed Product(s) are intended for * * *.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       1
<PAGE>

       1.5    "Annual Period" for reporting and payments due under this
Agreement, shall be based on the calendar year, to begin on January 1 and end on
December 31 of each year during the Term of the Agreement.

       1.6    "Confidential Information" shall mean any information of a
technical, scientific or commercial character which is proprietary to one of the
Parties hereto or is otherwise in the legitimate possession of such party under
an obligation of confidence, and which is confidential and/or not generally
available from public sources, and includes any and all documents, electronic
data, plans, photographs, apparatus and samples containing such information.
Information that is assembled from a variety of public sources by use of
Confidential Information to guide a search of such sources, shall also be deemed
Confidential Information.

       1.7    "Field of Use" shall mean * * *.

       1.8    "First Year Patent Expenses" shall mean all out-of pocket fees,
costs, and expenses paid or incurred by PRF in the year following the Effective
Date for filing, prosecuting, and maintaining the Licensed Patents in the
Licensed Territory.

       1.9    "Indication" means one of the following: (i) central nervous
system injuries, diseases, and disorders; (ii) traumatic brain injury; (iii)
stroke; (iv) peripheral nervous system injuries, diseases, and disorders; and
(v) neurodegenerative disorders.

       1.10   "Licensed Patents" shall mean all U.S. patent applications, Patent
Cooperation Treaty patent applications, or foreign patent applications filed by
PRF and related to a Technology, and all divisionals, continuations,
continuations-in-part, or other patent applications that claim priority from
such patent applications; any patent(s) issuing from the foregoing applications
and all extensions, reexaminations, and reissues of such patent(s); and any
patents issuing from patent applications that are related to a Technology and
that are filed by PRF subsequent to the Effective Date, and all extensions,
reexaminations, and reissues of such patents.

       1.11   "Licensed IP" shall mean all know-how, technical information,
copyrights and renewals, designs, drawings, specifications, manufacturing
methods, and all other information owned by Purdue Research Foundation and
related to the Technologies.

       1.12   "Licensed Product(s)" shall mean products or services, the
development, manufacture, use or sale of which are covered by the Licensed
Patents and/or Licensed IP, or that would otherwise constitute an infringement
of the Licensed Patents and/or Licensed IP.

       1.13   "Licensed Territory" means worldwide.

       1.14   "OFS + Inosine Technology" means the technology covered by PRF
Disclosure No. * * *, U.S. Patent Application No. * * *, and/or PCT Patent
Application No. * * *.

       1.15   "Other Patent Expenses" shall mean all out-of pocket fees, costs,
and expenses paid or incurred by PRF that are not Past Patent Expenses or First
Year Patent Expenses.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       2
<PAGE>

       1.16   "Payment Due Date" means the dates on which royalties and payments
shall be due and payable, which date shall be sixty (60) days after the end of
each Reporting Period.

       1.17   "Past Patent Expenses" shall mean out-of-pocket fees, costs, and
expenses paid or incurred by PRF prior to the Effective Date for filing,
prosecuting, and maintaining the Licensed Patents in the Licensed Territory.

       1.18   "PRF Indemnitees" shall mean PRF, PRF's officers, directors and
employees, Purdue University, Purdue University officers, researchers and
employees, and their heirs, executors, administrators, and legal
representatives.

       1.19   "Projected Market" shall mean total estimated sales of a Licensed
Product for a period that is the greater of (i) * * *, or (ii) * * *.

       1.20   "Quarterly Gross Receipts" means the gross payments and other
consideration (whether cash or non-cash) accrued or received (net of product
returns) in a Reporting Period in consideration for provision by LICENSEE,
Sublicensees, and Affiliates of Licensed Product(s) to customers, including but
not limited to: fees or other consideration for sale, license, or lease of
Licensed Product(s), or other service or product fees otherwise related in any
way to Licensed Product(s). This definition includes all amounts for
installation, products, maintenance, and/or other services provided in
conjunction with Licensed Product(s). Where a sale, gift, use, or other
disposition of a Licensed Product is transacted for value other than cash, the
term "Quarterly Gross Receipts" shall mean, per unit of said Licensed Product,
the fair market value of said Licensed Product as evidenced by the retail price
realized for sales of comparable Licensed Product during the immediately
preceding three (3) month period. For avoidance of doubt, Licensed Products
provided in an amount that is customary in the industry to hospitals,
physicians, researchers, clinical research organizations, and others at no
charge or at a discount for purposes including sales promotion and product
testing and evaluation shall not be considered a transaction "for value other
than cash." Quarterly Gross Receipts excludes the following items as separately
charged and enumerated on an invoice to customers: packing, transportation and
insurance charges; and import, export, excise, sales, use and value added taxes,
and customs duties. Sales of Licensed Products by a Sublicensee under a
Sublicense shall be treated as Quarterly Gross Receipts for payment of the
royalty specified in Article 4.2., and any income to LICENSEE from the
Sublicense in excess of this amount shall be excluded from Quarterly Gross
Receipts hereunder.

       1.21   "Reporting Period" means quarterly periods ending on March 31,
June 30, September 30, and December 31 of each Annual Period during the term of
this Agreement.

       1.22   "Sublicense" shall mean a sublicensing agreement or arrangement
between LICENSEE and a third party by which the third-party is licensing
Licensed Patents or Licensed IP. The holder of a Sublicense is a "Sublicensee."

       1.23   "Technology" shall mean one of the areas of technology listed in
EXHIBIT A hereof.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       3
<PAGE>

       1.24   "Third Party Agreement" shall mean a separate patent license that
LICENSEE must obtain from a third party so that LICENSEE may develop, make, have
made, use, and/or sell a Licensed Product.

       1.25   "Third Party Payments" shall mean the amounts paid by LICENSEE
under a Third Party Agreement.

       1.26   "Trial Product" shall mean a Licensed Product as it is undergoing
clinical trials prior to approval for * * *.

                          Article 2.  GRANT OF LICENSE

       2.1    License. Subject to compliance with this Agreement, and subject to
Articles 2.3 and 2.6, PRF grants, and LICENSEE accepts, an exclusive license to
the Licensed Patents and Licensed IP to develop, make, have made, use, and sell
Licensed Products on a royalty-bearing basis in the Field of Use in the Licensed
Territory and for issuance of corresponding Sublicenses directly between
LICENSEE and a Sublicensee in accordance with Article 2.5.

       2.2    No Implied License. The license and right granted in this
Agreement shall not be construed to confer any rights upon LICENSEE by
implication, estoppel, or otherwise.2.3 Retained License. PRF retains on behalf
of itself, Purdue University, and any research collaborators, a royalty-free
right and license under the Licensed Patents and Licensed IP for research and
educational purposes only.

       2.4    Government Rights. The Licensed Patents and Licensed IP, or
portions thereof may have been developed with financial or other assistance
through grants or contracts funded by the United States government. LICENSEE
acknowledges that in accordance with Public Law 96-517 and other statutes,
regulations, and Executive Orders as now exist or may be amended or enacted, the
United States government may have certain rights in the Licensed Patents and
Licensed IP. LICENSEE shall take all action necessary to enable PRF to satisfy
its obligations under any federal law relating to the Licensed Patents and
Licensed IP and inventions, including any right of the United States government
to a noncommercial use license. In the event PRF has or acquires such knowledge,
PRF shall inform LICENSEE if any Licensed Patent and Licensed IP, or portion
thereof, was developed with financial or other assistance through grants or
contracts funded by the United States government.

       2.5    Sublicenses. Provided that written approval of PRF is obtained in
advance, which approval shall not be unreasonably withheld, LICENSEE shall have
the right to grant one or more Sublicenses consistent with license granted to
LICENSEE in this Agreement. LICENSEE shall remain responsible for the operations
of its Sublicensees relevant to this Agreement as if such operations were
carried out by LICENSEE, including but not limited to the payment of all fees
and royalties due under this Agreement, whether or not such payments are made to
LICENSEE by its Sublicensees. LICENSEE shall provided to PRF a copy of each
executed Sublicense on or before the 15th day following the execution of the
Sublicense.

       2.6    OFS + Inosine Technology. To the extent the Licensed Patents
pertain to OFS + Inosine Technology, PRF grants, and the LICENSEE accepts, a
nonexclusive license to such

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       4
<PAGE>

Licensed Patents to develop, make, have made, use, and sell Licensed Products on
a royalty-bearing basis in the Field of Use in the Licensed Territory and for
issuance of corresponding Sublicenses directly between LICENSEE and a
Sublicensee in accordance with Article 2.5. Upon written notice from PRF to
LICENSEE that PRF has the authority to grant LICENSEE an exclusive license from
OFS + Inosine Technology, the license granted to LICENSEE under this Agreement
for OFS + Inosine Technology shall become exclusive, without necessity for
further action. The date of said written notice from PRF to LICENSEE is the
"Nonexclusivity Conversion Date." Royalties due under section 4.2 and Exhibit A
on Quarterly Gross Receipts received prior to the Nonexclusivity Conversion Date
solely in consideration for Licensed Products covered solely by the OFS +
Inosine Technology (and not any other Licensed Patents and/or Licenses IP) shall
be discounted by * * *% from the royalty rate stated in Exhibit A for OFT +
Inosine Technology.

                   Article 3.  DILIGENCE AND COMMERCIALIZATION

       3.1    Diligence and Commercialization. LICENSEE shall exercise
reasonable business judgment throughout the term of this Agreement in executing
LICENSEE's Development Plan, as attached in Exhibit B.

       3.2    Lack of Diligence. If PRF reasonably concludes that LICENSEE is
not in compliance with Article 3.1 with respect to any Technology at any time
after * * * from the Effective Date, then PRF shall have the right to terminate
LICENSEE's rights to that Technology under this License Agreement, as provided
under Article 12. Prior to exercising said right, PRF shall give notice to
LICENSEE stating the basis for its conclusion and, upon the request of PRF,
LICENSEE shall show cause why the license granted hereunder to that Technology
should not be terminated. Failure of LICENSEE to cure within ninety (90) days
from the date of PRF's notice shall automatically (not subject to any
requirement for further cause, legal process, or other action of PRF or
LICENSEE) cause LICENSEE's rights under this License Agreement to that
Technology to be deemed to be conclusively terminated on the 90th day following
said declaration. LICENSEE's rights with respect to other Technologies will
survive such termination.

       3.3    Financial Capability. At all times during the term of this
license, LICENSEE shall maintain the financial capability to comply with Article
3.1. Upon inquiry from PRF regarding said capability, LICENSEE shall provide any
requested assurances and disclosures and shall permit PRF to inspect LICENSEE's
financial records at agreed times during LICENSEE's normal business hours. Such
records are the Confidential Information of LICENSEE. If PRF reasonably
concludes that LICENSEE is not in compliance with this Article 3.3 with respect
to any Technology at any time after * * * from the Effective Date, then PRF
shall have the right to terminate LICENSEE's rights under this License Agreement
to that Technology, as provided under Article 12. Prior to exercising said
right, PRF shall give notice to LICENSEE stating the basis for its conclusion
and, upon the request of PRF, LICENSEE shall show cause why the license granted
hereunder should not be terminated. Failure of LICENSEE to cure within ninety
(90) days from the date of PRF's notice shall automatically (not subject to any
requirement for further cause, legal process, or other action of PRF or
LICENSEE) cause this License Agreement

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       5
<PAGE>

to be deemed to be conclusively terminated on the 90th day following said
declaration. LICENSEE's rights with respect to other Technologies will survive
such termination.

                      Article 4.  CONSIDERATION FOR LICENSE

       4.1    Licensing Fee. As partial consideration for the license granted to
LICENSEE under this Agreement, within fourteen (14) days after PRF executes
LICENSEE's Subscription Agreement, LICENSEE shall issue to PRF * * * shares,
without par value, of LICENSEE's common stock. Such consideration shall be in
lieu of an up front fee for the grant of rights hereunder.

       4.2    Royalties. As further consideration for the grant of rights
hereunder, LICENSEE will pay PRF a royalty. The royalty rates are set forth in
Exhibit A. In the event that a Licensed Product falls within multiple Technology
categories as set forth in Exhibit A, the effective royalty rate for the
Licensed Product will be the highest of the royalty rates applicable to the
multiple Technology categories.

       4.2    Milestone Payments. As further consideration for the grant of
rights hereunder, LICENSEE will pay PRF certain payments for Licensed Product
approval milestones, as further described in Exhibit D.

       4.3    Maintenance Payments. LICENSEE shall pay PRF the following
maintenance payments:

              Annual Period                       Maintenance Payment
              -------------                       -------------------
                2006-2008                                * * *
                   2009                                  * * *
                2010-2012                                * * *
        (greater or equal to)2013                        * * *

Such maintenance payments are due * * * following the last day of the Annual
Period. Any royalties accrued during the Annual Period or other payments made by
LICENSEE to PRF during the Annual Period are creditable against the maintenance
payment owed for that Annual Period.

       4.4    Convertibility. * * *.

       4.5    Third Party Payments. LICENSEE may reduce the amounts paid to PRF
for a Reporting Period by the amount of any Third Party Payments made in the
Reporting Period, provided, however, that such reductions over the course of an
Annual Period shall be limited to * * * of the amounts paid and/or owed by
LICENSEE to PRF for the Annual Period.

                        Article 5.  PAYMENTS AND REPORTS

       5.1    Payments. Unless otherwise set forth herein, all payments required
under this Agreement shall be payable on or before the Payment Due Date for each
payment to PRF at the

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       6
<PAGE>

address set forth below in Article 5.6. If originating outside of the United
States, payments shall be made by wire transfer to an account identified by PRF.

       5.2    Currency Conversion. All royalties to be paid by LICENSEE
hereunder shall be paid in U.S. Dollars. To the extent that Quarterly Gross
Receipts received by LICENSEE and Affiliates in any calendar quarter are
received in currencies other than U.S. Dollars, for purposes of calculating the
royalties due hereunder, such Quarterly Gross Receipts shall be converted to
U.S. Dollars at the exchange rate existing between the U.S. Dollar and the
relevant currency on the last day of such calendar quarter, as such rate is
reported by the Wall Street Journal.

       5.3    Interest. Payments required under this Agreement shall, if
overdue, bear interest until payment at a per annum rate * * * per month
following a * * * past due date. The payment of such interest shall not
foreclose PRF from exercising any other rights it may have because any payment
is late.

       5.4    Progress Reports. LICENSEE will provide PRF with annual progress
reports detailing the activities of LICENSEE relevant to the LICENSEE's
Development Plan. Such progress reports shall be delivered within thirty (30)
days of the end of each Annual Period.

       5.5    Royalty Reports. LICENSEE agrees to make written reports and
payments of earned royalties to PRF on or before the Payment Due Date for
Quarterly Gross Receipts accrued in each preceding Reporting Period during the
Term of this Agreement. For each Reporting Period, LICENSEE will provide
information consistent with Exhibit C, Royalty Reports Requirements. Concurrent
with the issuance of each report, LICENSEE shall pay PRF the amounts due for the
Reporting Period, including minimum annual royalties due and payable concurrent
with the final Reporting Period of each Annual Period. Reports are required even
if no earned royalties are due.

       5.6    Delivery of Payments and Reports. All payments and reports due
under this Agreement shall be delivered in person or via the United States mail
or private carrier to the following address:

                   Purdue Research Foundation
                   Office of Technology Commercialization
                   3000 Kent Ave.
                   West Lafayette, IN 47906
                   Attention: Director

                               Article 6.  RECORDS

       6.1    Records of Sales. During the term of this Agreement and for a
period of three (3) years thereafter, LICENSEE shall keep at its principal place
of business true and accurate records of all sales and other revenues derived
from Licensed Products by LICENSEE, Sublicensees, and Affiliates in accordance
with generally accepted accounting principles in the respective country where
such sales occur and in such form and manner so that all royalties owed to PRF
may be readily and accurately determined. LICENSEE shall furnish PRF copies of
such records upon PRF's request, which shall not be made more often than once
per Annual Period.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       7
<PAGE>

       6.2    Audit of Records. PRF shall have the right, from time to time at
agreed times during normal business hours through an independent certified
public accountant, to examine the records of LICENSEE and Affiliates to include,
but not be limited to, sales invoice registers, sales analysis reports, original
invoices, inventory records, price lists, Sublicense and distributor agreements,
accounting general ledgers, and sales tax returns, in order to verify the
calculation of any royalties payable under this Agreement. Such examination and
verification shall not occur more than once each calendar year. Unless otherwise
agreed in writing by LICENSEE, the fees and expenses of performing such
examination and verification shall be borne by PRF. If such examination reveals
an underpayment by LICENSEE of more than * * * for any quarter examined,
LICENSEE shall pay PRF the amount of such underpayment plus interest in
accordance with Article 5 and shall reimburse PRF for all expenses of the
accountant performing the examination.

                         Article 7.  PATENT PROSECUTION

       7.1    Prosecution and Maintenance of Licensed Patents. The filing,
prosecution, and maintenance of the Licensed Patents shall be the primary
responsibility of PRF. PRF shall promptly inform LICENSEE as to all developments
with respect to Licensed Patents. LICENSEE shall be afforded reasonable
opportunities to advise PRF and cooperate with PRF in such prosecution and
maintenance. At LICENSEE's request, PRF shall file and prosecute additional
United States and foreign patent applications on the Technology, with such
patent application to be included as Licensed Patents upon their filing.
LICENSEE may recommend the attorneys, agents, and/or firms to which PRF
delegates tasks relating to the drafting, filing, prosecution, and maintenance
of the Licensed Patents, and PRF shall give due consideration to LICENSEE's
recommendation when selecting such attorneys, agents, and/or firms. LICENSEE
shall be entitled to communicate directly with the attorneys, agents, and/or
firms selected by PRF concerning the Licensed Patents, provided, however, that
PRF shall be the final authority with respect to actions taken by such
attorneys, agents, and/or firms with respect to the Licensed Patents. PRF shall
provide any written consents and waivers required to permit the LICENSEE to
communicate directly with such attorneys, agents, and/or firms concerning the
Licensed Patents. Subsequent to the Effective Date, PRF shall not authorize any
activity that will incur expenses for which reimbursement by LICENSEE is
required under Article 7.3 of this Agreement unless PRF obtains the prior
consent of LICENSEE. If LICENSEE should fail to timely make reimbursement for
patent expenses incurred under this paragraph as required in Article 7.3 of this
Agreement, PRF shall have no further obligation to prosecute or maintain the
Licensed Patents. LICENSEE, upon ninety (90) days advance written notice to PRF,
may advise PRF that it no longer wishes to pay expenses for filing, prosecuting
or maintaining one or more Licensed Patent(s). PRF may, at its option, elect to
pay such expenses or permit such Licensed Patent(s) to become abandoned or
lapsed. If PRF elects to pay such expenses, such patent(s) shall not be subject
to any license granted to LICENSEE hereunder.

       7.2    Extension of Licensed Patents. LICENSEE may request that PRF have
the normal term of any Licensed Patent extended or restored under a country's
procedure of extending life for time lost in government regulatory approval
processes, and the expense of same shall be borne by LICENSEE. LICENSEE shall
assist PRF to take whatever action is necessary to obtain such extension. In the
case of such extension, royalties pursuant to Article 4 hereof shall be

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       8
<PAGE>

payable until the end of the extended life of the patent. In the event that
LICENSEE does not elect to extend Licensed Patents, PRF may, at its own expense,
effect the extension of such Licensed Patents. If PRF elects to pay such
expenses, such extended Licensed Patents shall not be subject to any license
granted to LICENSEE hereunder for the period subsequent to the expiration of the
normal term of the Licensed Patent.

       7.3    Reimbursement for Patent Expenses.

              7.3.1  Past Patent Expenses. Past Patent Expenses amount to * * *.
       LICENSEE shall reimburse PRF for such Past Patent Expenses on or before
       the first anniversary of the Effective Date.

              7.3.2  First Year Patent Expenses. PRF shall notify LICENSEE from
       time to time of the amount of any First Year Patent Expenses.
       Reimbursement for such First Year Patent Expenses shall not be due from
       LICENSEE until the first anniversary of the Effective Date.

              7.3.3  Other Patent Expenses. PRF shall notify LICENSEE from time
       to time of the amount of any Other Patent Expenses. LICENSEE shall
       deliver reimbursement to PRF for such Other Patent Expenses within thirty
       (30) days after LICENSEE receives notification from PRF of such Other
       Patent Expenses.

              7.3.4  Invoices. All reimbursements under Articles 7.3.1, 7.3.2,
       and 7.3.3 are subject to LICENSEE receiving a correctly rendered invoice
       from PRF. An invoice is correctly rendered if: (i) the amount for which
       reimbursement is sought is correctly calculated; (ii) the invoice is set
       out in a manner that enables LICENSEE to ascertain the expenses to which
       the invoice relates and the amount payable in respect of each expense
       item; and (iii) the invoice is accompanied (where reasonably requested by
       LICENSEE) by documentation substantiating all expenses for which
       reimbursement is sought.

                      Article 8.  ABATEMENT OF INFRINGEMENT

       8.1    Notice of Infringement. LICENSEE acknowledges that the Licensed
Patents are of great value to PRF, and therefore, LICENSEE promises to take all
appropriate measures reasonably necessary to protect PRF's interests therein.
LICENSEE shall not permit any entity, individual or firm to have access to the
Licensed Patents, except as authorized in this Agreement or as authorized by
law. LICENSEE shall promptly inform PRF of any suspected infringement of any
Licensed Patents.

       8.2    Right to Institute Action. LICENSEE shall have the first right
(but not the obligation) to notify the infringer and/or initiate legal
proceedings to abate the infringement. Upon failure by LICENSEE to begin or
continue to do so timely, PRF shall have the right (but not the obligation) to
take those steps on behalf of itself and LICENSEE.

       8.3    Monetary Recovery. If LICENSEE leads proceedings to abate and
remedy infringement, any monetary recovery from the infringement of Licensed
Patents except for punitive damages, less the documented amount of any attorneys
fees and costs incurred by

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       9
<PAGE>

LICENSEE in the prosecution of said infringement claim, shall be treated as
Quarterly Gross Receipts. If LICENSEE leads proceedings to abate and remedy
infringement, any punitive damages recovered from the infringement of Licensed
Patents, less the documented amount of any attorneys fees and costs incurred by
LICENSEE in the prosecution of said infringement claim, * * *. If PRF leads
proceedings to abate and remedy infringement, any monetary recovery from the
infringement of Licensed Patents shall * * *. If LICENSEE and PRF jointly lead
proceedings to abate and remedy infringement, any monetary recovery (net of the
Parties' respective litigation costs) from the infringement of Licensed Patents
shall * * *.

       8.4    Attornev Fees and Costs. LICENSEE and PRF shall each bear their
own attorney fees and costs incurred in the prosecution of any infringement
proceedings initiated under this Article.

                           Article 9.  CONFIDENTIALITY

       9.1    Agreement Terms. Neither party shall, without the express written
consent of the other party, for any reason or at any time either during or
subsequent to the term of this Agreement disclose to third parties the financial
terms set forth in this Agreement, except upon a subpoena or other court order
made with appropriate provision for protection of confidential information.

       9.2    Technical and Patent Information. LICENSEE shall not, without the
express written consent of PRF, for any reason or at any time either during or
subsequent to the term of this Agreement disclose to third parties any
information disclosed in any pending patent applications or any other
information pertaining to the Licensed Patents and Licensed IP disclosed to
LICENSEE by PRF or Purdue University and designated as confidential (such
information shall be collectively referred to as "Information"). This obligation
of nondisclosure shall not extend to information:

              (a)    which LICENSEE can demonstrate through documentation to
       have been within LICENSEE's legitimate possession prior to the time of
       disclosure of such Information to LICENSEE by PRF or Purdue University;

              (b)    which is in the public domain as of the date hereof or
       comes into the public domain hereafter through no fault of LICENSEE;

              (c)    which is disclosed to LICENSEE by a third party having
       legitimate possession of the information and the unrestricted right to
       make such disclosure.

       9.3    LICENSEE's Confidential Information. Any and all Confidential
Information belonging to the LICENSEE that PRF may receive in the course of
performance of this Agreement or during the term of this Agreement or
thereafter, including without limitation Confidential Information received from
Affiliates, contractors, employees, consultants or other agents of LICENSEE,
shall be treated by PRF as strictly confidential. Unless PRF receives the prior
written consent of LICENSEE, PRF shall not, directly or indirectly, use any
Confidential Information belonging to LICENSEE for any purpose except pursuant
to the provisions of this

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       10
<PAGE>

Agreement. PRF shall not disclose any Confidential Information belonging to
LICENSEE to any third party without the prior written consent of LICENSEE.

       9.4    Prior Agreements. The provisions of this Agreement supersede and
shall be substituted for any terms of any prior confidentiality agreement
between LICENSEE and PRF which are not consistent with this Agreement.

    Article 10.  LIMITED WARRANTY MERCHANTABILITY AND EXCLUSION OF WARRANTIES

       10.1   Limited Warranty. Each Party warrants to the other that it is
fully empowered to enter into this Agreement. PRF represents, in good faith and
to the best of its knowledge, that there are not, as of the date of this
Agreement, any claims, demands, suits, or judgments against it that in any
manner would or might impair or interfere with PRF's performance of the license
granted by PRF to LICENSEE under this Agreement. PRF represents and warrants
that, as of the Effective Date and at all times during the term of this
Agreement, (i) PRF is and shall be the sole owner of all right, title, and
interest in and to the Licensed Patents and Licensed IP, excepting the OFS +
Inosine Technology; (ii) PRF is and shall be entitled to grant the rights
granted hereunder; (iii) for each Licensed Patent, PRF, by and through and in
reliance upon counsel of record for the Licensed Patents, has exercised due
diligence in ascertaining the identity of all inventors of the inventions
covered by the Licensed Patents; and (iv) for each Licensed Patent, PRF has
obtained a binding assignment from each inventor.

       10.2   Merchantability and Exclusion of Warranties. Subject to the
foregoing, PRF does not warrant the validity of any Licensed Patent or
invention. PRF does not warrant the content contained in the Licensed Patents or
inventions or that they will be error free or that any defects will be
corrected. PRF makes no representation whatsoever with regard to the scope or
commercial potential or profitability or income of or from the Licensed Patents
or inventions or that such Licensed Patents or inventions may be exploited by
LICENSEE without infringing any rights of any other party. PRF makes no covenant
either to defend any infringement charge by a third party or to institute action
against infringers of Licensed Patents or inventions. PRF does not warrant that
the Licensed Patents or inventions will meet LICENSEE's or any of LICENSEE's
customer's specific requirements. LICENSEE warrants that it possesses the
necessary expertise and skill to make, and has made, its own evaluation of the
capabilities, safety, utility, and commercial application of the Licensed
Patents and inventions. ACCORDINGLY, EXCEPT FOR THE WARRANTIES SET FORTH IN
ARTICLE 10.1, THE LICENSED PATENTS AND INVENTIONS ARE PROVIDED "AS IS." PRF
MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED
PATENTS AND INVENTIONS AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED WARRANTIES WITH
RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF
LICENSED PATENTS AND INVENTIONS.

               Article 11.  DAMAGES INDEMNIFICATION AND INSURANCE

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       11
<PAGE>

       11.1   No Liability. Each party to this Agreement covenants not to seek
punitive, exemplary, indirect or consequential damages (excepting only lost
profits in the form of lost royalties as a remedy for breach of LICENSEE's
obligations under Article 3) from the other party to this Agreement with respect
to matters arising under or in connection with the subject matter of this
Agreement.

       11.2   Indemnification by LICENSEE. LICENSEE shall defend, indemnify and
hold Indemnitees harmless from any and all claims, demands, actions and causes
of action asserted by a third party against PRF, whether groundless or not, in
connection with any and all injuries, losses, damages or liability of any kind
whatsoever arising, directly or indirectly, out of use, exploitation,
distribution, or sale of Licensed Patents or Licensed Product(s) by or through
the LICENSEE, Affiliates, or Sublicensees. Under no circumstance shall the
indemnification obligation under this section encompass any claim, demand,
action or cause of action with reference to 1) a clinical trial commenced prior
to the effective date of this Agreement and undertaken without direct
participation of LICENSEE, or 2) a device manufactured prior to the effective
date of this Agreement. This indemnification obligation shall include, without
limiting the generality of the foregoing, reasonable attorney fees and other
costs or expenses incurred in connection with the defense of any and all such
claims, demands, actions, or causes of action.

       11.3   Insurance. Without limiting LICENSEE's indemnity obligations,
within ninety (90) days of the commercial distribution of any Licensed Product
or on the date of initiation of any human trials whichever occurs sooner,
LICENSEE shall acquire a liability insurance policy and shall further maintain
said policy throughout the term of this Agreement and for five (5) years
thereafter, said policy to cover PRF and Purdue University as named insureds
(with right to prior notice of cancellation) for all liabilities, claims,
damages, and actions arising from or relating to LICENSEE's, Sublicensee's, and
Affiliate's exercise of a license under this Agreement, including but not
limited to product liability and other matters within the scope of LICENSEE's
indemnity obligations under this Agreement, said coverage to be in an amount no
less than * * * per occurrence for bodily injury and * * * per occurrence for
property damage, subject to a reasonable aggregate amount.

       11.4   Notice of Claims. LICENSEE shall promptly notify PRF of all claims
involving the PRF Indemnitees and will provide PRF information requested by PRF
for evaluation of each such claim.

                        Article 12.  TERM AND TERMINATION

       12.1   Term. Unless otherwise extended in writing by mutual agreement of
the Parties, this Agreement will remain valid and in force for ten (10) years
from the date of the first sale of a Licensed Product in any country, or until
the expiration date of the last of the valid claims of the last to expire of the
Licensed Patents, whichever is greater. Such extension may include additional
provisions or modifications to terms herein as applicable, and such changes
shall be negotiated between the Parties and a written amendment to this
Agreement will be made as appropriate.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       12
<PAGE>

       12.2   Termination by PRF. If LICENSEE should at any time default or
commit any breach of any covenant or any obligation of the license, and should
fail to remedy any default or breach within ninety (90) days of LICENSEE'S
receipt of written notice, PRF may, at its sole option, terminate this license
by notice in writing to the LICENSEE.

       12.3   Notice of Bankruptcy. If LICENSEE: (a) liquidates and ceases to
carry on its business, (b) becomes "insolvent" (as such term is defined in the
United States Bankruptcy Code, as amended from time to time), or (c) voluntarily
seeks, consents to or acquiesces in the benefits of any bankruptcy or similar
debtor-relief laws, then PRF may summarily terminate this Agreement without
prior notice and without prejudice to any other remedy to which PRF may be
entitled at law or in equity or elsewhere under this Agreement, by giving
written notice of termination to LICENSEE.

       12.4   Failure to Enforce. The failure of either party at any time, or
for any period of time, to enforce any of the provisions of this Agreement shall
not be construed as a waiver of such provisions or as a waiver of the right of
such party thereafter to enforce each and every such provision.

       12.5   Termination by LICENSEE.

              12.5.1 For Convenience. LICENSEE may terminate this Agreement at
       its sole discretion upon * * * written notice to PRF. In the event of
       such termination, LICENSEE agrees, upon the request of PRF, to provide
       PRF with all existing data in support of registration of Licensed
       Products for the Field of Use with the relevant federal agencies. PRF
       shall have the unrestricted right to provide such data to third parties.

              12.5.2 For Cause. LICENSEE may, at its sole option, terminate this
       Agreement by notice in writing to PRF (i) if PRF should at any time
       default or commit any breach of any covenant or any obligation under this
       Agreement, and should fail to remedy any default or breach within * * *
       of PRF's receipt of written notice from LICENSEE; or (ii) if PRF (a)
       liquidates and ceases to carry on its business, (b) becomes "insolvent"
       (as such term is defined in the United States Bankruptcy Code, as amended
       from time to time), or (c) voluntarily seeks, consents to or acquiesces
       in the benefits of any bankruptcy or similar debtor-relief laws.

       12.6   Effect. Upon termination of the Agreement by either party,
LICENSEE and Affiliates shall cease all uses of the Licensed Patents and
Licensed IP. LICENSEE shall return, or at PRF's direction destroy, all plans,
drawings, papers, notes, writings and other documents, samples, organisms,
biological materials and models pertaining to the Licensed Patents and Licensed
IP, retaining no copies, and LICENSEE and Affiliates shall cease manufacturing,
processing, producing, using, or selling Licensed Products; provided, however,
that LICENSEE and Affiliates may continue to sell in the ordinary course of
business for a period of * * * reasonable quantities of Licensed Products which
are fully manufactured and in LICENSEE's normal inventory at the date of
termination if (a) all monetary obligations of LICENSEE to PRF have been
satisfied and (b) royalties on such sales are paid to PRF in the amounts and in
the manner provided in this Agreement. However, nothing in this Article 12.6
shall be construed to

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       13
<PAGE>

release either party of any obligation which matured prior to the effective date
of such termination.

       12.7   Assignment of Sublicenses. If LICENSEE has granted any Sublicenses
pursuant to Article 2.5 prior to the termination of this Agreement, then
LICENSEE shall be deemed to have assigned such Sublicense agreements to PRF,
including the right to receive revenues due and payable under any Sublicense.

       12.8   Survival. The provisions of Articles 9, 10, 11, 14.2, 14.3, and
14.9 of this Agreement shall remain in full force and effect notwithstanding the
termination of this Agreement. Termination of this Agreement shall not relieve
LICENSEE of its obligation to pay any amount owed to PRF hereunder as of the
date of termination.

                              Article 13.  NOTICES

Except as otherwise provided herein, all notices and other communications shall
be hand delivered, sent by private overnight mail service, or sent by registered
or certified U.S. mail, postage prepaid, return receipt requested, and addressed
to the party to receive such notice or other communication at the address given
below, or such other address as may hereafter be designated by notice in
writing:

           If to PRF:          Purdue Research Foundation
                               Office of Technology Commercialization
                               3000 Kent Ave.
                               West Lafayette, IN 47906
                               Facsimile: (765) 496-1277
                               ATTN: Director

           If to LICENSEE:     Andara Life Science, Inc.
                               848 Wedgewood Lane
                               Carmel, Indiana 46033
                               Facsimile: (317) 846-9453
                               ATTN: Mark A. Carney

           With a copy to:     Ice Miller
                               One American Square, Box 82001
                               Indianapolis, Indiana
                               46282-0200
                               Facsimile: (317) 236-2219
                               ATTN: Thomas A. Walsh

Such notices or other communications shall be effective upon receipt by an
employee, agent or representative of the receiving party authorized to receive
notices or other communications sent or delivered in the manner set forth above.

                           Article 14.  MISCELLANEOUS

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       14
<PAGE>

       14.1   Export Controls. LICENSEE acknowledges that PRF is subject to
United States laws and regulations controlling the export of technical data,
computer software, laboratory prototypes, and other commodities and that PRF's
obligations under this Agreement are contingent upon compliance with applicable
United States export laws and regulations. The transfer of technical data and
commodities may require a license from the cognizant agency of the United States
government or written assurances by LICENSEE that LICENSEE shall not export data
or commodities to certain foreign countries without the prior approval of
certain United States agencies. PRF neither represents that an export license
shall not be required nor that, if required, such export license shall issue.

       14.2   Jurisdiction, Venue, Choice of Law, and Attorney's Fees. Any
justiciable dispute between LICENSEE and PRF shall be determined solely and
exclusively under Indiana law by a court of competent jurisdiction in Indiana,
subject to the provisions of Article 14.3. The prevailing party in any litigated
dispute shall be entitled to reimbursement of its attorney's fees and costs.

       14.3   Arbitration. Any controversy or claim arising between the Parties
in connection with this Agreement shall be determined by private binding
arbitration before a single arbitrator. Such arbitration shall be conducted in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association ("AAA") that are in effect on the date that the demand for
arbitration is given. If PRF and LICENSEE are unable to agree on the identity of
a single arbitrator within ten (10) business days of notice of a demand for
arbitration provided by one party to the other hereunder, then the AAA
arbitrator selection rules shall apply; provided, however, that any arbitrator
selected under the AAA selection rules shall also be an attorney admitted and in
good standing in Indiana. Any arbitration under this Agreement shall be held in
Indianapolis, Indiana. Any demand for arbitration shall include detail
sufficient to establish the nature of the dispute (including the claims asserted
and the material issues with respect thereto) and shall be delivered to the
other party concurrent with delivery to AAA. Discovery from the other party
shall be limited to requests for production of documents and to depositions. No
additional formal discovery from the other party (e.g., interrogatories or
requests for admissions) shall be permitted except by mutual consent or as
approved by the arbitrator for good cause shown. The arbitrator's decision shall
be in writing, and shall describe in detail the legal reasoning adopted by the
arbitrator in support of the decision. In rendering a decision, the arbitrator
shall follow the law of the United States of America and of the jurisdiction set
forth in Article 14.2 hereof and shall not use equitable or other principles
which would permit the arbitrator to ignore the Agreement or the law. The
arbitrator's decision shall be final and binding on the Parties, provided,
however, that errors of law may be appealed to a court of competent jurisdiction
for review. Any award by the arbitrator shall be subject to all dollar and other
limitations set forth in this Agreement. The arbitrator shall have no authority
to award treble, exemplary, or punitive damages of any type under any
circumstances. Judgment upon the award rendered by the arbitrator may be entered
in any court having jurisdiction thereof. Any party to this Agreement may bring
an action, including a summary or expedited proceeding, to compel arbitration of
any controversy or claim to which this Agreement applies in any court having
jurisdiction over such action. Nothing in this Article 14.3 shall limit the
right of either PRF or LICENSEE to obtain from a court provisional or ancillary
remedies such as, but not limited to,

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       15
<PAGE>

injunctive relief, before, during or after the pendency of any arbitration
proceeding brought pursuant to this Agreement, or in lieu of such proceedings.

       14.4   Legal Compliance. LICENSEE shall comply with all laws an d
regulations relating to its manufacture, processing, producing, use, selling, or
distributing of Licensed Products. LICENSEE shall not knowingly take any action
which would cause PRF or Purdue University to violate any laws and regulations.

       14.5   Independent Contractor. LICENSEE's relationship to PRF shall be
that of a licensee only. LICENSEE shall not be the agent of PRF and shall have
no authority to act for or on behalf of PRF in any matter. Persons retained by
LICENSEE as employees or agents shall not by reason thereof be deemed to be
employees or agents of PRF.

       14.6   Patent Marking. LICENSEE shall mark Licensed Products sold in the
United States in accordance with United States law concerning the marking of
patented items. Licensed Products manufactured or sold in other countries shall
be marked in compliance with the intellectual property laws in force in such
foreign countries.

       14.7   Use of Names. Each party shall obtain the written approval of the
other party prior to making use of such other party's name for any commercial
purpose, except as required by law. As an exception to the foregoing, both
LICENSEE and PRF shall have the right to publicize the existence of this
Agreement; however, neither LICENSEE nor PRF shall disclose the terms and
conditions of this Agreement without the other party's consent, except as
required by law.

       14.8   Place of Execution. This Agreement and any subsequent
modifications or amendments hereto shall be deemed to have been executed in the
State of Indiana, U.S.A.

       14.9   Governing Law. This Agreement and all amendments, modifications,
alterations, or supplements hereto, and the rights of the Parties hereunder,
shall be construed under and governed by the laws of the State of Indiana and
the United States of America.

       14.10  Severability. All rights and restrictions contained herein maybe
exercised and shall be applicable and binding only to the extent that they do
not violate any applicable laws and are intended to be limited to the extent
necessary so that they will not render this Agreement illegal, invalid or
unenforceable. If any provision or portion of any provision of this Agreement
not essential to the commercial purpose of this Agreement shall be held to be
illegal, invalid or unenforceable by a court of competent jurisdiction, it is
the intention of the Parties that the remaining provisions or portions thereof
shall constitute their agreement with respect to the subject matter hereof, and
all such remaining provisions or portions thereof shall remain in full force and
effect. To the extent legally permissible, any illegal, invalid or unenforceable
provision of this Agreement shall be replaced by a valid provision which will
implement the commercial purpose of the illegal, invalid or unenforceable
provision. In the event that any provision essential to the commercial purpose
of this Agreement is held to be illegal, invalid or unenforceable and cannot be
replaced by a valid provision which will implement the commercial purpose of
this Agreement, this Agreement and the rights granted herein shall terminate.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       16
<PAGE>

       14.11  Force Maieure. Any delays in, or failure of, performance of any
party to this Agreement shall not constitute default hereunder, or give rise to
any claim for damages, if and to the extent caused by occurrences beyond the
control of the party affected, including, but not limited to, acts of God,
strikes or other work stoppages; civil disturbances, fires, floods, explosions,
riots, war, rebellion, sabotage, acts of governmental authority or failure of
governmental authority to issue licenses or approvals which may be required.

       14.12  Assignment. PRF shall not assign or transfer this Agreement or any
of its rights and obligations hereunder without the prior written consent of
LICENSEE. This Agreement and LICENSEE's rights and obligations under this
Agreement shall not be assigned or transferred without the prior written consent
of PRF (which consent shall not be unreasonably withheld but may be conditioned
for the reasonable protection of consideration promised to PRF pursuant to
Article 4); provided, however, that LICENSEE may, without prior consent of PRF,
assign or transfer this Agreement and its right and obligations under this
Agreement (i) to any wholly owned subsidiary of LICENSEE or to any other
Affiliate of LICENSEE, but in the case of any assignment or transfer to an
Affiliate (other than a wholly owned subsidiary of LICENSEE) only if no equity
holder in LICENSEE on the date of the transaction has a direct or indirect
equity interest in the Affiliate in any capacity other than as an equity holder
in LICENSEE, (ii) to any successor by merger or consolidation with LICENSEE in
which PRF's equity interests in LICENSEE is exchanged for securities, cash or
other property on the same basis as that of other equity holders of LICENSEE of
the same class (as a class), (iii) to the purchaser of all or substantially all
of the assets of LICENSEE on an arm's-length basis, or (iv) to the purchaser of
any substantial portion of the assets (or a line of business) of LICENSEE on an
arm's-length basis, other than a sale of all or substantially all of the assets
of LICENSEE which is governed solely by subsection (iii) above; provided,
however that in the event of a transaction governed by this subsection (iv), PRF
shall be entitled, at its option, to put all of its equity interests in LICENSEE
to LICENSEE for purchase by LICENSEE at a price equal to the value of PRF's
equity interests in LICENSEE in the event of a hypothetical, arm's -length,
contemporaneous sale of substantially all of the assets of LICENSEE (including
this Agreement and all rights and obligations hereunder) at fair market value on
the date of the applicable transaction (determined by mutual agreement of PRF
and LICENSEE or in the absence of agreement on such fair market value within a
reasonable period of time as determined by a mutually agreed upon independent
investment banking firm, the fees and expenses of which shall be borne equally
by PRF and LICENSEE), but only if PRF gives written notice to LICENSEE of the
exercise of such put right within twenty (20) days following receipt of written
notice from LICENSEE of the transaction. Any permitted assignee of LICENSEE
shall assume all obligations of LICENSEE under this Agreement. As used herein,
the term "permitted assignee(s)" shall mean and include any assignee to whom
LICENSEE's right and interest under this Agreement are assigned or transferred
without violation of this Agreement. Any purported assignment or transfer in
violation of this Section 14.12 shall be void. Subject to the limitations on
assignment herein, this Agreement shall be binding upon and inure to the benefit
of the direct and indirect successors in interest and assigns of LICENSEE.

       14.13  Entire Agreement. This Agreement constitutes the entire agreement
between PRF and LICENSEE with respect to the subject matter hereof and shall not
be modified,

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       17
<PAGE>

amended or terminated except as herein provided or except by another agreement
in writing executed by the Parties hereto.

                       THIS SPACE LEFT DELIBERATELY BLANK

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       18
<PAGE>

IN WITNESS WHEREOF, PRF and LICENSEE have caused this Agreement to be signed by
their duly authorized representatives, under seal, as of the day and year
indicated above.

PURDUE RESEARCH FOUNDATION                   ANDARA LIFE SCIENCES, INC.

/s/ Joseph B. Hornett                        /s/ Mark A. Carney
-----------------------------------          -----------------------------------
Joseph B. Hornett                            Mark A. Carney
Senior VP and Treasurer                      President

Date: 2/28/05                                Date: 2/28/05

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

                                       19
<PAGE>

                            EXHIBIT A-1: Technologies

* * *

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                    EXHIBIT B-1: LICENSEE'S Development Plan

FUNDING:

LICENSEE shall accomplish one of the following options:

       1)     * * *; or

       2)     * * *; or

       3)     * * *.

DEVELOPMENT PLAN:

       1)     * * *

       2)     * * *

       3)     * * *

       4)     * * *

       5)     * * *

* * *

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                     EXHIBIT C: Royalty Reports Requirements

(1)    Product or Service Name/Identification and all information necessary for
       determination of applicable "Technology" categorization under Exhibit A.

(2)    Product Number

(3)    Units sold

(4)    Quarterly Gross Receipts per Technology category under Exhibit A

(5)    Total Revenue Subject to Royalty

(8)    Wall Street Journal Conversion Rate (if applicable)

(9)    Converted U.S. Dollars (if applicable)

(10)   Minimum Royalty Due (if applicable)

(11)   Sublicense Income (all sources)

(12)   Sublicense Royalty Rate (if applicable)

(13)   Sublicense Royalty Due (if applicable)

(14)   Total Royalty Due

(15)   Names and Addresses of all Sublicensees and Distributors (if applicable)

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                          EXHIBIT D: Milestone Payments

  Terms Applicable to Licensed Product Approval Milestones Achieved by LICENSEE

1.     Milestone payments shall be due * * * following the date LICENSEE
achieves the milestone.

2.     Milestone payments shall be in accordance with TABLE I, and shall accrue
by Technology. LICENSEE shall not be required to pay more than one (1) milestone
payment at each Level for each Technology, with the amount of the milestone
payment determined by the Projected Market of the first Trial Product to achieve
the particular Level. For example, assume there is a first Trial Product under
the 4-AP Derivative Technology. The Trial Product has a Projected Market of $1
billion and achieves Level I and Level II milestones but fails to achieve Level
III. LICENSEE will be obligated to pay PRF * * * upon achievement of Level I and
* * * upon achievement of Level II. Next, assume there is a second Trial Product
under the 4-AP Derivative Technology. This Trial Product has a Projected Market
of $6 billion and achieves all Levels I-IV. LICENSEE will be obligated to pay
PRF only for achievement of Level III and IV, i.e., * * * and * * *,
respectively. Finally, assume there is a third Trial Product under the 4-AP
Derivative Technology. This Trial Product has a Projected Market of $4 billion
and achieves all Levels I-IV. LICENSEE will not be obligated to pay PRF any
milestone payments for this third Trial Product.

3.     Prior to * * *, the parties will determine the Technology in good faith.
If the parties cannot reach agreement on the Technology, the determination will
be referred to a mutually agreeable third party whose determination will be
binding. The parties will pay equal shares of any charges incurred through the
use of the mutually agreeable third party. In the event LICENSEE is invoiced
directly by the third party and pays PRF's share of the charges, LICENSEE has
the right to deduct the amount paid by LICENSEE for which PRF is responsible
from any fixture amount LICENSEE owes to PRF. In the event PRF is invoiced
directly by the third party and pays LICENSEE's share of the charges, LICENSEE
shall add the amount paid by PRF for which LICENSEE is responsible to any future
amount LICENSEE owes to PRF.

4.     Prior to * * *, the parties will determine the Projected Market in good
faith. If the parties cannot reach agreement on the Projected Market, the
determination will be referred to a mutually agreeable third party whose
determination will be binding. This process will repeat prior to the conclusion
of any Phase III Trial, and again prior to Marketing Launch. * * *.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission. TABLE I

<PAGE>

---------------------------------------------------------------------
                                            PROJECTED MARKET
                                      -------------------------------
MILESTONE              Level          * * *        * * *        * * *
---------------------------------------------------------------------
* * *                    I            * * *        * * *        * * *
---------------------------------------------------------------------
* * *                   II            * * *        * * *        * * *
---------------------------------------------------------------------
* * *                   III           * * *        * * *        * * *
---------------------------------------------------------------------
* * *                   IV            * * *        * * *        * * *
---------------------------------------------------------------------

        Terms Applicable to Licensed Product Approval Milestones Achieved
                                by a Sublicensee

1.     In the event a Sublicensee is responsible for a Trial Product, and the
Sublicense provides for payments to LICENSEE upon the achievement by Sublicensee
of approval milestones, such payments shall be shared with PRF on the following
basis:

         * * *........  * * * % to PRF
         * * *........  * * * % to PRF
         * * *........  * * * % to PRF

2.     The foregoing amounts shall be in lieu of any other milestone payments
from LICENSEE for the corresponding Technology and Level.

3.     Prior to * * *, the parties will determine the Technology in good faith.
If the parties cannot reach agreement on the Technology, the determination will
be referred to a mutually agreeable third party whose determination will be
binding. The parties will pay equal shares of any charges incurred through the
use of the mutually agreeable third party. In the event LICENSEE is invoiced
directly by the third party and pays PRF's share of the charges, LICENSEE has
the right to deduct the amount paid by LICENSEE for which PRF is responsible
from any future amount LICENSEE owes to PRF. In the event PRF is invoiced
directly by the third party and pays LICENSEE's share of the charges, LICENSEE
shall add the amount paid by PRF for which LICENSEE is responsible to any future
amount LICENSEE owes to PRF.

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                                 AMENDMENT #1 TO
                           EXCLUSIVE LICENSE AGREEMENT

THIS AMENDMENT, made and entered into this 29th day of July, 2005 amends the
Agreement executed February 28, 2005, (hereinafter AGREEMENT) between Purdue
Research Foundation (hereinafter known as PRF) and Andara Life Science, Inc.
(hereinafter known as LICENSEE).

NOW THEREFORE, the parties hereto do hereby agree as follows:

1.     EXHIBIT A IS AMENDED TO INCLUDE THE FOLLOWING:

       a.     * * *

       b.     * * *

       c.     * * *

       d.     * * *

       e.     * * *

All other terms and conditions of the original agreement remain unchanged and in
effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
date first above written.

PURDUE RESEARCH FOUNDATION                    ANDARA LIFE SCIENCE, INC.

By: /s/ Joseph B. Hornett                     By: /s/ Mark A. Carney
    --------------------------------              ------------------------------
    Joseph B. Hornett                             Mark A. Carney
    Senior Vice President                         President

    Date: 8/8/05                                  Date: 8/8/05

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                         AMENDMENT TO LICENSE AGREEMENT
                                     BETWEEN
            PURDUE RESEARCH FOUNDATION AND ANDARA LIFE SCIENCE, INC.

This Amendment (hereinafter "Amendment") made and entered into as of the latest
date below, by and between Purdue Research Foundation (hereinafter "PRF") and
Andara Life Science, Inc. (hereinafter "LICENSEE"), hereby amends the LICENSE
AGREEMENT (Agreement ID 1011), between PRF and LICENSEE and dated February 28,
2005 (hereinafter "Agreement"). In the event of a conflict between any provision
of the Agreement and any provision of this Amendment, the provision of this
Amendment shall prevail. Unless otherwise defined in this Amendment, capitalized
terms in this Amendment shall have the same meaning as in the Agreement.

1.     Article 1.14 of the Agreement shall be deleted in its entirety and
replaced by the following:

              1.14   "OFS + Inosine Technology" means the technology covered by
       PRF Disclosure No. * * *, U.S. Patent Application No. * * *, and/or PCT
       Patent Application No. * * *, all divisionals, continuations,
       continuations-in-part, or other patent applications that claim priority
       from such patent applications; any patent(s) issuing from the foregoing
       applications and all extensions, reexaminations, and reissues of such
       patent(s).

2.     Article 2.6 of the Agreement shall be deleted in its entirety and
replaced by the following:

              2.6    OFS + Inosine Technology. To the extent the Licensed
       Patents pertain to OFS + Inosine Technology, PRF grants, and LICENSEE
       accepts, an exclusive license of all of PRF's right, title, and interest
       in and to the Licensed Patents to develop, make, have made, use, and sell
       Licensed Products on a royalty-bearing basis in the Field of Use in the
       Licensed Territory, and to issue corresponding Sublicenses directly
       between Licensee and a Sublicensee in accordance with Article 2.5.
       LICENSEE acknowledges that the exclusive license from PRF does not confer
       exclusive rights in the OFS + Inosine Technology, as PRF is not the sole
       owner of rights in the OFS + Inosine Technology. Therefore, Royalties due
       under Article 4.2 and Exhibit A on Quarterly Gross Receipts solely in
       consideration for Licensed Products covered solely by the OFS + Inosine
       Technology (and not any other Licensed Patents and/or Licensed IP) shall
       be discounted by * * * % from the royalty rate stated in Exhibit A for
       OFS + Inosine Technology.

2.     Article 4.2 of the Agreement, entitled "Royalties," shall be deleted in
its entirety and replaced by the following:

              4.2    Royalties. As further consideration for the grant of rights
       hereunder, LICENSEE will pay PRF a royalty. The royalty rates are set
       forth in Exhibit A, as amended by Article 2.6. In the event that a
       Licensed Product falls within multiple

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

       Technology categories as set forth in Exhibit A, the effective royalty
       rate for the Licensed Product will be the highest of the royalty rates
       applicable to the multiple Technology categories.

3.     The parties acknowledge that there is a second Article 4.2 in the
Agreement entitled "Milestone Payments," which is not affected by this
Amendment.

       Except as amended and modified by this Amendment, the Agreement shall
otherwise remain in full force and effect, and the PRF and LICENSEE hereby
ratify and confirm the same.

The terms and conditions of this Amendment are agreed to by:

PURDUE RESEARCH FOUNDATION               ANDARA LIFE SCIENCE, INC.

/s/ Joseph B. Hornett                    /s/ Mark A. Carney
-----------------------------------      ---------------------------------------
Signature                                Signature

8/9/05                                   8/9/05
-----------------------------------      ---------------------------------------
Date                                     Date

J. B. Hornett                            Mark A. Carney
-----------------------------------      ---------------------------------------
Name                                     Name

Sr. VP & Treasurer                       President & CEO
-----------------------------------      ---------------------------------------
Title                                    Title

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                                 AMENDMENT #3 TO
                           EXCLUSIVE LICENSE AGREEMENT

THIS AMENDMENT, made and entered into this 19th day of January 2006 amends the
Agreement executed February 28, 2005, (hereinafter AGREEMENT) between Purdue
Research Foundation (hereinafter known as PRF) and Andara Life Science, Inc.
hereinafter known as (LICENSEE).

NOW THEREFORE, the parties hereto do hereby agree as follows:

Exhibit A is amended to include the following technology:

* * *

All other terms and conditions of the original agreement remain unchanged and in
effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
date first above written.

PURDUE RESEARCH FOUNDATION                  ANDARA LIFE SCIENCE, INC.

By: /s/ Joseph B. Hornett                   By: /s/ Mark A. Carney
    --------------------------------            --------------------------------
    Joseph B. Hornett                           Mark A. Carney
    Senior Vice President                       President

                                            Date: 1/19/2006

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

                        AMENDMENT #4 TO LICENSE AGREEMENT
                                     BETWEEN
            PURDUE RESEARCH FOUNDATION AND ANDARA LIFE SCIENCE, INC.

       This Amendment (hereinafter "Amendment") made and entered into as of the
9th day of February, 2006, by and between Purdue Research Foundation
(hereinafter "PRF" and Andara Life Science, Inc. (hereinafter "LICENSEE"),
hereby amends the LICENSE AGREEMENT (Agreement ID 1011), between PRF and
LICENSEE and dated February 28, 2005 (hereinafter "Agreement"). In the event of
a conflict between any provision of this Amendment and any provision of the
Agreement or a prior amendment thereof, the provision of this Amendment shall
prevail. Unless otherwise defined in this Amendment, capitalized terms in this
Amendment shall have the same meaning as in the Agreement. Except as amended and
modified by this Amendment, the Agreement and any prior amendment shall remain
in full force and effect, and PRF and LICENSEE hereby ratify and confirm the
same.

       In consideration of the mutual covenants and agreements contained herein
and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties agree to amend the Agreement as follows:

1.     Article 4.2 of the Agreement, entitled "Milestone Payments," shall be
deleted in its entirety and replaced by the following:

       "4.2 Milestone Payments. As further consideration for the grant of rights
       hereunder, where required under Exhibit A LICENSEE will pay PRF certain
       payments for Licensed Product approval milestones, as further described
       in Exhibit D."

2.     The parties acknowledge that there is a second Article 4.2 in the
Agreement, entitled "Royalties," which is not affected by this Amendment.

3.     PRF hereby excuses LICENSEE from the obligation under Article 5.4 of the
Agreement to submit a progress report detailing the activities of LICENSEE in
relation to the Development Plan for the Annual Period consisting of the
calendar year 2005. The foregoing shall not be interpreted as relieving LICENSEE
of any obligation to provide progress reports under Article 5.4 for future
Annual Periods.

4.     The following is added to the Agreement as new Article 9.5:

       "9.5 Technical and Patent Information. PRF shall not, without the express
       written consent of LICENSEE, for any reason or at any time either during
       or subsequent to the term of this Agreement, disclose to third parties
       any information. This obligation of nondisclosure shall not extend to
       Information that is in the public domain as of the date hereof or comes
       into the public domain hereafter through no fault of PRF."

5.     Article 11.3 of the Agreement, entitled "Insurance," shall be deleted in
its entirety and replaced by the following:

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

       "11.3 Insurance. Without limiting LICENSEE's indemnity obligations,
       within ninety (90) days of the commercial distribution of any Licensed
       Product or on the date of initiation of any human trials whichever occurs
       sooner, LICENSEE shall acquire a liability insurance policy and shall
       further maintain said policy throughout the term of this Agreement and
       for five (5) years thereafter, said policy to cover PRF and Purdue
       University as named insureds (with right to prior notice of cancellation)
       for all liabilities, claims, damages, and actions arising from or
       relating to LICENSEE'S, Sublicensee's, and Affiliate's exercise of a
       license under this Agreement, including but not limited to product
       liability and other matters within the scope of LICENSEE's indemnity
       obligations under this Agreement, said coverage to be in an amount no
       less than * * * per occurrence for bodily injury and * * * per occurrence
       for property damage, subject to a reasonable aggregate amount."

6.     EXHIBIT A to the Agreement shall be replaced by the EXHIBIT A-1 that is
attached hereto. All references to "Exhibit A" in the Agreement and any prior
amendment are replaced by "Exhibit A-1."

7.     EXHIBIT B to the Agreement shall be replaced by the EXHIBIT B-1 that is
attached hereto. All references to "Exhibit B" in the Agreement and any prior
amendment are replaced by "Exhibit B-1."

8.     This Amendment may be executed in one or more counterparts, each of which
will be deemed to be an original, but all of which shall constitute one and the
same instrument.

                             SIGNATURE PAGE FOLLOWS

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

<PAGE>

         The terms and conditions of this Amendment are agreed to by:

PURDUE RESEARCH FOUNDATION                 ANDARA LIFE SCIENCE, INC.

/s/ Joseph B. Hornett                      /s/ Mark A. Carney
-------------------------------------      -------------------------------------
Signature                                  Signature

-------------------------------------      -------------------------------------
Date                                       Date

-------------------------------------      -------------------------------------
Name                                       Name

-------------------------------------      -------------------------------------
Title                                      Title

*** Information redacted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]